Cognitive Decline in AD

A Cohort Study of Cognitive Decline in Alzheimer Disease

There is lack of information on the risk factors of accelerated cognitive decline in older people with Alzheimer disease (AD). The extent of neurodegeneration and white matter disease has been reported to be important factors. In addition there may be biomarkers e.g. inflammatory cytokines that can contribute to cognitive decline. The impact of care arrangement and physical activity may also be important. Insulin signaling is impaired in Alzheimer disease (AD).

We therefore propose to perform a cohort study of older people with AD. This will be based on an on-going AD registry which was designed to identify genetic biomarkers for AD. Detailed neurocognitive tests and lifestyle information are available. In addition, volumetric MRI brain scans were performed in all AD subjects. The hypothesis is that MRI brain volumes, serum biomarkers, physical activity, physical functioning are independently associated with cognitive decline in older people with AD. The objective is to identify risk factors of accelerated cognitive decline so that preventive measures can be designed to delay dependency in AD.

Study Overview

• Status: Recruiting
• Conditions: Alzheimer Disease

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: Timothy Kwok, MD; Phone Number: +852 35053145; Email: tkwok@cuhk.edu.hk
• Study Contact Backup: Name: Hazel Mok, BSc; Phone Number: +852 35053990; Email: hazelmok@cuhk.edu.hk

Study Locations

• Hong Kong
  • Hong Kong, Hong Kong
    • Recruiting
    • The Chinese University of Hong Kong
    • Contact: Timothy Kwok, MD; Phone Number: +852 35053145; Email: tkwok@cuhk.edu.hk
    • Contact: Joanna Cheng; Phone Number: +852 26367546; Email: chengoiyue@cuhk.edu.hk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years to 92 years (Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Subjects are recruited from the geriatric outpatient clinics or memory clinic.

Description

Inclusion Criteria:

• Sufficient Cantonese competency for cognitive test
• Clinical diagnosis of AD
• FAST test staging 3-5

Exclusion Criteria:

• Subjects who refuse blood taking procedure
• No reliable family caregiver informant (person contact at least once a month)

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Alzheimer's Disease Assessment Scale-cognitive subscale ADAS-COG	Cognitive assessment for dementia	24-Months

Collaborators and Investigators

• Sponsor: Chinese University of Hong Kong

Study record dates

Study Major Dates

• Study Start (Actual): December 13, 2018
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: May 8, 2019
• First Submitted That Met QC Criteria: May 9, 2019
• First Posted (Actual): May 13, 2019

Study Record Updates

• Last Update Posted (Actual): August 21, 2024
• Last Update Submitted That Met QC Criteria: August 20, 2024
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Cognition Disorders; Alzheimer Disease; Cognitive Dysfunction
• Other Study ID Numbers: 2018.274

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No